The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial (Q36614280)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2006

Language	Label	Description	Also known as
English	The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial	scientific article published on June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

phase II clinical trial

0 references

multicenter clinical trial

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gunter von Minckwitz

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

S-E Al-Batran

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

J Bischoff

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A Atmaca

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

U Kleeberg

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

I Meuthen

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

G Morack

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

W Lerbs

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

D Hecker

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

J Sehouli

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A Knuth

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

E Jager

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

94

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1615-1620

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

30 September 2017

Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

30 September 2017

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

30 September 2017

Pegylated liposomal doxorubicin in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

30 September 2017

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

30 September 2017

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

30 September 2017

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

30 September 2017

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

28 June 2018

Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

28 June 2018

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

20 September 2018

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361305

20 September 2018

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603158

21 January 2018

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16685267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin-induced cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16685267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16685267

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603158

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16685267%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36614280&oldid=2199090926"